Regencell Bioscience (NASDAQ:RGC) Reaches New 1-Year Low – Time to Sell?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) hit a new 52-week low on Thursday . The company traded as low as $8.55 and last traded at $8.56, with a volume of 470564 shares. The stock had previously closed at $11.08.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Regencell Bioscience presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The firm’s 50 day moving average is $23.14 and its 200-day moving average is $25.54.

Regencell Bioscience (NASDAQ:RGC) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

Several large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP purchased a new stake in Regencell Bioscience during the 4th quarter worth approximately $92,000. Amundi acquired a new stake in shares of Regencell Bioscience in the 1st quarter worth approximately $219,000. Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience during the 4th quarter valued at $275,000. Bank of America Corp DE grew its position in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares during the period. Finally, Vident Advisory LLC grew its stake in shares of Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares during the period. Institutional investors and hedge funds own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.